Summary
You may be eligible for this study if you are aged 18 years or older, have a diagnosis of multiple myeloma (MM), have received treatments before for MM, and the MM has returned or not responded to the most recent treatment.
Eligible participants will be randomly allocated to one of two treatment arms.
In the Experimental Arm, participants will receive a targeted medicine called Elranatamab which will be given as an injection under the skin at the study clinic about once a week. This may change to a smaller number of shots later in the study.
In the Active Comparator Arm, participants will receive a combination therapy selected by the study doctor. This will include 2-3 different medicines commonly used to treat MM. These will be taken by mouth (at home or at the study clinic) AND will either be given as: an injection under the skin or through a needle in the vein (IV) at the study clinic. The number of times these medicines will be taken depends on what combination therapy the study doctor selects.
Participants may continue to receive elranatamab or a combination therapy until their MM is no longer responding. The study team will see how each participant is doing with the study treatment during regular visits at the study clinic. The study team will continue to follow-up with participants after study treatment with telephone contacts (or visits).
The study will compare the experiences of people receiving elranatamab to those people receiving a combination therapy. This will help learn about the safety and how effective elranatamab is.